drugset / Trial / NCT01768338
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
Timeline
- Start
- 2013-02
- Primary completion
- 2016-03
- Completion
- 2017-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 3 ug/kg | — |
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 30 ug/kg | — |
| Subject | Ofatumumab | Monoclonal antibody | 1000 mg | Intravenous |